Pharma & Healthcare
Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
- May 05, 25
- ID: 223180
- Pages: 98
- Figures: 95
- Views: 40
The global Chemotherapy Induced Peripheral Neuropathy Treatment market size was US$ 1895 million in 2024 and is forecast to a readjusted size of US$ 2907 million by 2031 with a CAGR of 6.4% during the forecast period 2025-2031.
CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.
There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.
Americas is the largest market with about 47% market share. Europe is follower, accounting for about 27% market share.
The key players are Aptinyx Inc, Asahi Kasei Pharma Corp, Regenacy Pharmaceuticals, MAKScientific LLC, Metys Pharmaceuticals AG, Nemus Bioscience Inc, PledPharma, Sova Pharmaceuticals Inc, DermaXon LLC, Kineta Inc, Krenitsky Pharmaceuticals Inc, PeriphaGen, Apexian Pharma, WinSanTor etc.
The global Chemotherapy Induced Peripheral Neuropathy Treatment market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
Aptinyx Inc
Asahi Kasei Pharma Corp
Regenacy Pharmaceuticals
MAKScientific LLC
Metys Pharmaceuticals AG
Nemus Bioscience Inc
PledPharma
Sova Pharmaceuticals Inc
DermaXon LLC
Kineta Inc
Krenitsky Pharmaceuticals Inc
PeriphaGen
Apexian Pharma
WinSanTor
By Type: (Dominant Segment vs High-Margin Innovation)
Calcium Channel α2-delta Ligands
Antidepressants
Opioids
Others
By Application: (Core Demand Driver vs Emerging Opportunity)
Platinum Agents
Taxanes
Vinca Alkaloids
Others
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Aptinyx Inc in Europe)
- Emerging Product Trends: Calcium Channel α2-delta Ligands adoption vs. Antidepressants premiumization
- Demand-Side Dynamics: Platinum Agents growth in China vs. Taxanes potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
Japan
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Chemotherapy Induced Peripheral Neuropathy Treatment market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Antidepressants in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Taxanes in India).
Chapter 6: Regional sales and revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
This is not just another market study. By fusing global trend analysis with hyper-local operational intelligence, we deliver:
- Risk-Controlled Market Entry: Navigate regulatory complexities in focus markets (e.g., China’s policies).
- Product Portfolio Optimization: Align offerings with regional preferences (e.g., Calcium Channel α2-delta Ligands dominance in Europe vs. Antidepressants demand in MEA).
- Competitor Counterstrategies: Decode player tactics in fragmented vs. consolidated markets.
CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.
There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.
Americas is the largest market with about 47% market share. Europe is follower, accounting for about 27% market share.
The key players are Aptinyx Inc, Asahi Kasei Pharma Corp, Regenacy Pharmaceuticals, MAKScientific LLC, Metys Pharmaceuticals AG, Nemus Bioscience Inc, PledPharma, Sova Pharmaceuticals Inc, DermaXon LLC, Kineta Inc, Krenitsky Pharmaceuticals Inc, PeriphaGen, Apexian Pharma, WinSanTor etc.
The global Chemotherapy Induced Peripheral Neuropathy Treatment market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
Aptinyx Inc
Asahi Kasei Pharma Corp
Regenacy Pharmaceuticals
MAKScientific LLC
Metys Pharmaceuticals AG
Nemus Bioscience Inc
PledPharma
Sova Pharmaceuticals Inc
DermaXon LLC
Kineta Inc
Krenitsky Pharmaceuticals Inc
PeriphaGen
Apexian Pharma
WinSanTor
By Type: (Dominant Segment vs High-Margin Innovation)
Calcium Channel α2-delta Ligands
Antidepressants
Opioids
Others
By Application: (Core Demand Driver vs Emerging Opportunity)
Platinum Agents
Taxanes
Vinca Alkaloids
Others
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Aptinyx Inc in Europe)
- Emerging Product Trends: Calcium Channel α2-delta Ligands adoption vs. Antidepressants premiumization
- Demand-Side Dynamics: Platinum Agents growth in China vs. Taxanes potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
Japan
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Chemotherapy Induced Peripheral Neuropathy Treatment market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Antidepressants in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Taxanes in India).
Chapter 6: Regional sales and revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
This is not just another market study. By fusing global trend analysis with hyper-local operational intelligence, we deliver:
- Risk-Controlled Market Entry: Navigate regulatory complexities in focus markets (e.g., China’s policies).
- Product Portfolio Optimization: Align offerings with regional preferences (e.g., Calcium Channel α2-delta Ligands dominance in Europe vs. Antidepressants demand in MEA).
- Competitor Counterstrategies: Decode player tactics in fragmented vs. consolidated markets.
1 Market Overview
1.1 Chemotherapy Induced Peripheral Neuropathy Treatment Product Scope
1.2 Chemotherapy Induced Peripheral Neuropathy Treatment by Type
1.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2020 & 2024 & 2031)
1.2.2 Calcium Channel α2-delta Ligands
1.2.3 Antidepressants
1.2.4 Opioids
1.2.5 Others
1.3 Chemotherapy Induced Peripheral Neuropathy Treatment by Application
1.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Comparison by Application (2020 & 2024 & 2031)
1.3.2 Platinum Agents
1.3.3 Taxanes
1.3.4 Vinca Alkaloids
1.3.5 Others
1.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Estimates and Forecasts (2020-2031)
1.4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size in Value Growth Rate (2020-2031)
1.4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size in Volume Growth Rate (2020-2031)
1.4.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price Trends (2020-2031)
1.5 Assumptions and Limitations
2 Market Size and Prospective by Region
2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Retrospective Market Scenario by Region (2020-2025)
2.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2020-2025)
2.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2020-2025)
2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Estimates and Forecasts by Region (2026-2031)
2.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Estimates and Forecasts by Region (2026-2031)
2.3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Region (2026-2031)
2.4 Major Region and Emerging Market Analysis
2.4.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Prospective (2020-2031)
2.4.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Prospective (2020-2031)
2.4.3 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Prospective (2020-2031)
3 Global Market Size by Type
3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Review by Type (2020-2025)
3.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2020-2025)
3.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2020-2025)
3.1.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2020-2025)
3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Estimates and Forecasts by Type (2026-2031)
3.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Type (2026-2031)
3.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Type (2026-2031)
3.2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price Forecast by Type (2026-2031)
3.3 Different Types Chemotherapy Induced Peripheral Neuropathy Treatment Representative Players
4 Global Market Size by Application
4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Review by Application (2020-2025)
4.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2020-2025)
4.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2020-2025)
4.1.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (2020-2025)
4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Estimates and Forecasts by Application (2026-2031)
4.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Application (2026-2031)
4.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Application (2026-2031)
4.2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price Forecast by Application (2026-2031)
4.3 New Sources of Growth in Chemotherapy Induced Peripheral Neuropathy Treatment Application
5 Competition Landscape by Players
5.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Players (2020-2025)
5.2 Global Top Chemotherapy Induced Peripheral Neuropathy Treatment Players by Revenue (2020-2025)
5.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment as of 2024)
5.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Company (2020-2025)
5.5 Global Key Manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment, Manufacturing Sites & Headquarters
5.6 Global Key Manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment, Product Type & Application
5.7 Global Key Manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment, Date of Enter into This Industry
5.8 Manufacturers Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company
6.1.1.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2020-2025)
6.1.1.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2020-2025)
6.1.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2020-2025)
6.1.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application (2020-2025)
6.1.4 North America Chemotherapy Induced Peripheral Neuropathy Treatment Major Customer
6.1.5 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company
6.2.1.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2020-2025)
6.2.1.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2020-2025)
6.2.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2020-2025)
6.2.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application (2020-2025)
6.2.4 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Major Customer
6.2.5 Europe Market Trend and Opportunities
6.3 Japan Market: Players, Segments, Downstream and Major Customers
6.3.1 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company
6.3.1.1 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2020-2025)
6.3.1.2 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2020-2025)
6.3.2 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2020-2025)
6.3.3 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application (2020-2025)
6.3.4 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Major Customer
6.3.5 Japan Market Trend and Opportunities
7 Company Profiles and Key Figures
7.1 Aptinyx Inc
7.1.1 Aptinyx Inc Company Information
7.1.2 Aptinyx Inc Business Overview
7.1.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.1.4 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.1.5 Aptinyx Inc Recent Development
7.2 Asahi Kasei Pharma Corp
7.2.1 Asahi Kasei Pharma Corp Company Information
7.2.2 Asahi Kasei Pharma Corp Business Overview
7.2.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.2.4 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.2.5 Asahi Kasei Pharma Corp Recent Development
7.3 Regenacy Pharmaceuticals
7.3.1 Regenacy Pharmaceuticals Company Information
7.3.2 Regenacy Pharmaceuticals Business Overview
7.3.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.3.4 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.3.5 Regenacy Pharmaceuticals Recent Development
7.4 MAKScientific LLC
7.4.1 MAKScientific LLC Company Information
7.4.2 MAKScientific LLC Business Overview
7.4.3 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.4.4 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.4.5 MAKScientific LLC Recent Development
7.5 Metys Pharmaceuticals AG
7.5.1 Metys Pharmaceuticals AG Company Information
7.5.2 Metys Pharmaceuticals AG Business Overview
7.5.3 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.5.4 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.5.5 Metys Pharmaceuticals AG Recent Development
7.6 Nemus Bioscience Inc
7.6.1 Nemus Bioscience Inc Company Information
7.6.2 Nemus Bioscience Inc Business Overview
7.6.3 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.6.4 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.6.5 Nemus Bioscience Inc Recent Development
7.7 PledPharma
7.7.1 PledPharma Company Information
7.7.2 PledPharma Business Overview
7.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.7.4 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.7.5 PledPharma Recent Development
7.8 Sova Pharmaceuticals Inc
7.8.1 Sova Pharmaceuticals Inc Company Information
7.8.2 Sova Pharmaceuticals Inc Business Overview
7.8.3 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.8.4 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.8.5 Sova Pharmaceuticals Inc Recent Development
7.9 DermaXon LLC
7.9.1 DermaXon LLC Company Information
7.9.2 DermaXon LLC Business Overview
7.9.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.9.4 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.9.5 DermaXon LLC Recent Development
7.10 Kineta Inc
7.10.1 Kineta Inc Company Information
7.10.2 Kineta Inc Business Overview
7.10.3 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.10.4 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.10.5 Kineta Inc Recent Development
7.11 Krenitsky Pharmaceuticals Inc
7.11.1 Krenitsky Pharmaceuticals Inc Company Information
7.11.2 Krenitsky Pharmaceuticals Inc Business Overview
7.11.3 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.11.4 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.11.5 Krenitsky Pharmaceuticals Inc Recent Development
7.12 PeriphaGen
7.12.1 PeriphaGen Company Information
7.12.2 PeriphaGen Business Overview
7.12.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.12.4 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.12.5 PeriphaGen Recent Development
7.13 Apexian Pharma
7.13.1 Apexian Pharma Company Information
7.13.2 Apexian Pharma Business Overview
7.13.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.13.4 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.13.5 Apexian Pharma Recent Development
7.14 WinSanTor
7.14.1 WinSanTor Company Information
7.14.2 WinSanTor Business Overview
7.14.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.14.4 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.14.5 WinSanTor Recent Development
8 Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Cost Analysis
8.1 Chemotherapy Induced Peripheral Neuropathy Treatment Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment
8.4 Chemotherapy Induced Peripheral Neuropathy Treatment Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
9.1 Marketing Channel
9.2 Chemotherapy Induced Peripheral Neuropathy Treatment Distributors List
9.3 Chemotherapy Induced Peripheral Neuropathy Treatment Customers
10 Chemotherapy Induced Peripheral Neuropathy Treatment Market Dynamics
10.1 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Trends
10.2 Chemotherapy Induced Peripheral Neuropathy Treatment Market Drivers
10.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Challenges
10.4 Chemotherapy Induced Peripheral Neuropathy Treatment Market Restraints
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.1.1 Research Programs/Design
12.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
12.1.2 Data Source
12.1.2.1 Secondary Sources
12.1.2.2 Primary Sources
12.2 Author Details
12.3 Disclaimer
1.1 Chemotherapy Induced Peripheral Neuropathy Treatment Product Scope
1.2 Chemotherapy Induced Peripheral Neuropathy Treatment by Type
1.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2020 & 2024 & 2031)
1.2.2 Calcium Channel α2-delta Ligands
1.2.3 Antidepressants
1.2.4 Opioids
1.2.5 Others
1.3 Chemotherapy Induced Peripheral Neuropathy Treatment by Application
1.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Comparison by Application (2020 & 2024 & 2031)
1.3.2 Platinum Agents
1.3.3 Taxanes
1.3.4 Vinca Alkaloids
1.3.5 Others
1.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Estimates and Forecasts (2020-2031)
1.4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size in Value Growth Rate (2020-2031)
1.4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size in Volume Growth Rate (2020-2031)
1.4.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price Trends (2020-2031)
1.5 Assumptions and Limitations
2 Market Size and Prospective by Region
2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Retrospective Market Scenario by Region (2020-2025)
2.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2020-2025)
2.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2020-2025)
2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Estimates and Forecasts by Region (2026-2031)
2.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Estimates and Forecasts by Region (2026-2031)
2.3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Region (2026-2031)
2.4 Major Region and Emerging Market Analysis
2.4.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Prospective (2020-2031)
2.4.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Prospective (2020-2031)
2.4.3 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Prospective (2020-2031)
3 Global Market Size by Type
3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Review by Type (2020-2025)
3.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2020-2025)
3.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2020-2025)
3.1.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2020-2025)
3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Estimates and Forecasts by Type (2026-2031)
3.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Type (2026-2031)
3.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Type (2026-2031)
3.2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price Forecast by Type (2026-2031)
3.3 Different Types Chemotherapy Induced Peripheral Neuropathy Treatment Representative Players
4 Global Market Size by Application
4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Review by Application (2020-2025)
4.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2020-2025)
4.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2020-2025)
4.1.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (2020-2025)
4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Estimates and Forecasts by Application (2026-2031)
4.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Application (2026-2031)
4.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Application (2026-2031)
4.2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price Forecast by Application (2026-2031)
4.3 New Sources of Growth in Chemotherapy Induced Peripheral Neuropathy Treatment Application
5 Competition Landscape by Players
5.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Players (2020-2025)
5.2 Global Top Chemotherapy Induced Peripheral Neuropathy Treatment Players by Revenue (2020-2025)
5.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment as of 2024)
5.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Company (2020-2025)
5.5 Global Key Manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment, Manufacturing Sites & Headquarters
5.6 Global Key Manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment, Product Type & Application
5.7 Global Key Manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment, Date of Enter into This Industry
5.8 Manufacturers Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company
6.1.1.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2020-2025)
6.1.1.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2020-2025)
6.1.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2020-2025)
6.1.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application (2020-2025)
6.1.4 North America Chemotherapy Induced Peripheral Neuropathy Treatment Major Customer
6.1.5 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company
6.2.1.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2020-2025)
6.2.1.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2020-2025)
6.2.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2020-2025)
6.2.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application (2020-2025)
6.2.4 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Major Customer
6.2.5 Europe Market Trend and Opportunities
6.3 Japan Market: Players, Segments, Downstream and Major Customers
6.3.1 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company
6.3.1.1 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2020-2025)
6.3.1.2 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2020-2025)
6.3.2 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2020-2025)
6.3.3 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application (2020-2025)
6.3.4 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Major Customer
6.3.5 Japan Market Trend and Opportunities
7 Company Profiles and Key Figures
7.1 Aptinyx Inc
7.1.1 Aptinyx Inc Company Information
7.1.2 Aptinyx Inc Business Overview
7.1.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.1.4 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.1.5 Aptinyx Inc Recent Development
7.2 Asahi Kasei Pharma Corp
7.2.1 Asahi Kasei Pharma Corp Company Information
7.2.2 Asahi Kasei Pharma Corp Business Overview
7.2.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.2.4 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.2.5 Asahi Kasei Pharma Corp Recent Development
7.3 Regenacy Pharmaceuticals
7.3.1 Regenacy Pharmaceuticals Company Information
7.3.2 Regenacy Pharmaceuticals Business Overview
7.3.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.3.4 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.3.5 Regenacy Pharmaceuticals Recent Development
7.4 MAKScientific LLC
7.4.1 MAKScientific LLC Company Information
7.4.2 MAKScientific LLC Business Overview
7.4.3 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.4.4 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.4.5 MAKScientific LLC Recent Development
7.5 Metys Pharmaceuticals AG
7.5.1 Metys Pharmaceuticals AG Company Information
7.5.2 Metys Pharmaceuticals AG Business Overview
7.5.3 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.5.4 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.5.5 Metys Pharmaceuticals AG Recent Development
7.6 Nemus Bioscience Inc
7.6.1 Nemus Bioscience Inc Company Information
7.6.2 Nemus Bioscience Inc Business Overview
7.6.3 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.6.4 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.6.5 Nemus Bioscience Inc Recent Development
7.7 PledPharma
7.7.1 PledPharma Company Information
7.7.2 PledPharma Business Overview
7.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.7.4 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.7.5 PledPharma Recent Development
7.8 Sova Pharmaceuticals Inc
7.8.1 Sova Pharmaceuticals Inc Company Information
7.8.2 Sova Pharmaceuticals Inc Business Overview
7.8.3 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.8.4 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.8.5 Sova Pharmaceuticals Inc Recent Development
7.9 DermaXon LLC
7.9.1 DermaXon LLC Company Information
7.9.2 DermaXon LLC Business Overview
7.9.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.9.4 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.9.5 DermaXon LLC Recent Development
7.10 Kineta Inc
7.10.1 Kineta Inc Company Information
7.10.2 Kineta Inc Business Overview
7.10.3 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.10.4 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.10.5 Kineta Inc Recent Development
7.11 Krenitsky Pharmaceuticals Inc
7.11.1 Krenitsky Pharmaceuticals Inc Company Information
7.11.2 Krenitsky Pharmaceuticals Inc Business Overview
7.11.3 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.11.4 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.11.5 Krenitsky Pharmaceuticals Inc Recent Development
7.12 PeriphaGen
7.12.1 PeriphaGen Company Information
7.12.2 PeriphaGen Business Overview
7.12.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.12.4 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.12.5 PeriphaGen Recent Development
7.13 Apexian Pharma
7.13.1 Apexian Pharma Company Information
7.13.2 Apexian Pharma Business Overview
7.13.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.13.4 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.13.5 Apexian Pharma Recent Development
7.14 WinSanTor
7.14.1 WinSanTor Company Information
7.14.2 WinSanTor Business Overview
7.14.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
7.14.4 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
7.14.5 WinSanTor Recent Development
8 Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Cost Analysis
8.1 Chemotherapy Induced Peripheral Neuropathy Treatment Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment
8.4 Chemotherapy Induced Peripheral Neuropathy Treatment Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
9.1 Marketing Channel
9.2 Chemotherapy Induced Peripheral Neuropathy Treatment Distributors List
9.3 Chemotherapy Induced Peripheral Neuropathy Treatment Customers
10 Chemotherapy Induced Peripheral Neuropathy Treatment Market Dynamics
10.1 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Trends
10.2 Chemotherapy Induced Peripheral Neuropathy Treatment Market Drivers
10.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Challenges
10.4 Chemotherapy Induced Peripheral Neuropathy Treatment Market Restraints
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.1.1 Research Programs/Design
12.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
12.1.2 Data Source
12.1.2.1 Secondary Sources
12.1.2.2 Primary Sources
12.2 Author Details
12.3 Disclaimer
List of Tables
Table 1. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (US$ Million) Growth Rate by Type (2020 & 2024 & 2031)
Table 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (US$ Million) Comparison by Application (2020 & 2024 & 2031)
Table 3. Global Market Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Region (2020-2025)
Table 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2020-2025)
Table 6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) Market Share by Region (2020-2025)
Table 7. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Region (2020-2025)
Table 8. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) Forecast by Region (2026-2031)
Table 9. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share Forecast by Region (2026-2031)
Table 10. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) Forecast by Region (2026-2031)
Table 11. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share Forecast by Region (2026-2031)
Table 12. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (K Units) & (2020-2025)
Table 13. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Type (2020-2025)
Table 14. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (US$ Million) & (2020-2025)
Table 15. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (US$/Unit) & (2020-2025)
Table 16. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (K Units) & (2026-2031)
Table 17. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (US$ Million) & (2026-2031)
Table 18. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (US$/Unit) & (2026-2031)
Table 19. Representative Players of Each Type
Table 20. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (K Units) & (2020-2025)
Table 21. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Application (2020-2025)
Table 22. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (US$ Million) & (2020-2025)
Table 23. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (US$/Unit) & (2020-2025)
Table 24. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (K Units) & (2026-2031)
Table 25. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (US$ Million) & (2026-2031)
Table 26. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (US$/Unit) & (2026-2031)
Table 27. New Sources of Growth in Chemotherapy Induced Peripheral Neuropathy Treatment Application
Table 28. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (K Units) & (2020-2025)
Table 29. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Company (2020-2025)
Table 30. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (US$ Million) & (2020-2025)
Table 31. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Company (2020-2025)
Table 32. Global Chemotherapy Induced Peripheral Neuropathy Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment as of 2024)
Table 33. Global Market Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Company (US$/Unit) & (2020-2025)
Table 34. Global Key Manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment, Manufacturing Sites & Headquarters
Table 35. Global Key Manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment, Product Type & Application
Table 36. Global Key Manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment, Date of Enter into This Industry
Table 37. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 38. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2020-2025) & (K Units)
Table 39. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company (2020-2025)
Table 40. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2020-2025) & (US$ Million)
Table 41. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Company (2020-2025)
Table 42. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2020-2025) & (K Units)
Table 43. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2020-2025)
Table 44. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2020-2025) & (K Units)
Table 45. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2020-2025)
Table 46. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2020-2025) & (K Units)
Table 47. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company (2020-2025)
Table 48. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2020-2025) & (US$ Million)
Table 49. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Company (2020-2025)
Table 50. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2020-2025) & (K Units)
Table 51. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2020-2025)
Table 52. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2020-2025) & (K Units)
Table 53. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2020-2025)
Table 54. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2020-2025) & (K Units)
Table 55. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company (2020-2025)
Table 56. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2020-2025) & (US$ Million)
Table 57. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Company (2020-2025)
Table 58. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2020-2025) & (K Units)
Table 59. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2020-2025)
Table 60. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2020-2025) & (K Units)
Table 61. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2020-2025)
Table 62. Aptinyx Inc Company Information
Table 63. Aptinyx Inc Description and Business Overview
Table 64. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 65. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 66. Aptinyx Inc Recent Development
Table 67. Asahi Kasei Pharma Corp Company Information
Table 68. Asahi Kasei Pharma Corp Description and Business Overview
Table 69. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 70. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 71. Asahi Kasei Pharma Corp Recent Development
Table 72. Regenacy Pharmaceuticals Company Information
Table 73. Regenacy Pharmaceuticals Description and Business Overview
Table 74. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 75. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 76. Regenacy Pharmaceuticals Recent Development
Table 77. MAKScientific LLC Company Information
Table 78. MAKScientific LLC Description and Business Overview
Table 79. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 80. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 81. MAKScientific LLC Recent Development
Table 82. Metys Pharmaceuticals AG Company Information
Table 83. Metys Pharmaceuticals AG Description and Business Overview
Table 84. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 85. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 86. Metys Pharmaceuticals AG Recent Development
Table 87. Nemus Bioscience Inc Company Information
Table 88. Nemus Bioscience Inc Description and Business Overview
Table 89. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 91. Nemus Bioscience Inc Recent Development
Table 92. PledPharma Company Information
Table 93. PledPharma Description and Business Overview
Table 94. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 95. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 96. PledPharma Recent Development
Table 97. Sova Pharmaceuticals Inc Company Information
Table 98. Sova Pharmaceuticals Inc Description and Business Overview
Table 99. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 100. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 101. Sova Pharmaceuticals Inc Recent Development
Table 102. DermaXon LLC Company Information
Table 103. DermaXon LLC Description and Business Overview
Table 104. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 105. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 106. DermaXon LLC Recent Development
Table 107. Kineta Inc Company Information
Table 108. Kineta Inc Description and Business Overview
Table 109. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 110. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 111. Kineta Inc Recent Development
Table 112. Krenitsky Pharmaceuticals Inc Company Information
Table 113. Krenitsky Pharmaceuticals Inc Description and Business Overview
Table 114. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 115. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 116. Krenitsky Pharmaceuticals Inc Recent Development
Table 117. PeriphaGen Company Information
Table 118. PeriphaGen Description and Business Overview
Table 119. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 120. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 121. PeriphaGen Recent Development
Table 122. Apexian Pharma Company Information
Table 123. Apexian Pharma Description and Business Overview
Table 124. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 125. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 126. Apexian Pharma Recent Development
Table 127. WinSanTor Company Information
Table 128. WinSanTor Description and Business Overview
Table 129. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 130. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 131. WinSanTor Recent Development
Table 132. Production Base and Market Concentration Rate of Raw Material
Table 133. Key Suppliers of Raw Materials
Table 134. Chemotherapy Induced Peripheral Neuropathy Treatment Distributors List
Table 135. Chemotherapy Induced Peripheral Neuropathy Treatment Customers List
Table 136. Chemotherapy Induced Peripheral Neuropathy Treatment Market Trends
Table 137. Chemotherapy Induced Peripheral Neuropathy Treatment Market Drivers
Table 138. Chemotherapy Induced Peripheral Neuropathy Treatment Market Challenges
Table 139. Chemotherapy Induced Peripheral Neuropathy Treatment Market Restraints
Table 140. Research Programs/Design for This Report
Table 141. Key Data Information from Secondary Sources
Table 142. Key Data Information from Primary Sources
List of Figures
Figure 1. Chemotherapy Induced Peripheral Neuropathy Treatment Product Picture
Figure 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (US$ Million) by Type (2020 & 2024 & 2031)
Figure 3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type in 2024 & 2031
Figure 4. Calcium Channel α2-delta Ligands Product Picture
Figure 5. Antidepressants Product Picture
Figure 6. Opioids Product Picture
Figure 7. Others Product Picture
Figure 8. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (US$ Million) by Application (2020 & 2024 & 2031)
Figure 9. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application in 2024 & 2031
Figure 10. Platinum Agents Examples
Figure 11. Taxanes Examples
Figure 12. Vinca Alkaloids Examples
Figure 13. Others Examples
Figure 14. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2020-2031) & (US$ Million)
Figure 16. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) Growth Rate (2020-2031)
Figure 17. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price Trends Growth Rate (2020-2031) & (US$/Unit)
Figure 18. Chemotherapy Induced Peripheral Neuropathy Treatment Report Years Considered
Figure 19. Global Market Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Figure 20. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region: 2020 VS 2024
Figure 21. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) Growth Rate (2020-2031)
Figure 22. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) Growth Rate (2020-2031)
Figure 23. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) Growth Rate (2020-2031)
Figure 24. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) Growth Rate (2020-2031)
Figure 25. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) Growth Rate (2020-2031)
Figure 26. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) Growth Rate (2020-2031)
Figure 27. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Type (2020-2025)
Figure 28. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Type (2026-2031)
Figure 29. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Type (2026-2031)
Figure 30. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Application (2020-2025)
Figure 31. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate by Application in 2020 & 2024
Figure 32. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Application (2026-2031)
Figure 33. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Application (2026-2031)
Figure 34. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Company (2024)
Figure 35. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Company (2024)
Figure 36. Global 5 Largest Chemotherapy Induced Peripheral Neuropathy Treatment Players Market Share by Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment: 2020 & 2024
Figure 37. Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 38. Manufacturing Cost Structure of Chemotherapy Induced Peripheral Neuropathy Treatment
Figure 39. Manufacturing Process Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment
Figure 40. Chemotherapy Induced Peripheral Neuropathy Treatment Industrial Chain
Figure 41. Channels of Distribution (Direct Vs Distribution)
Figure 42. Distributors Profiles
Figure 43. Bottom-up and Top-down Approaches for This Report
Figure 44. Data Triangulation
Figure 45. Key Executives Interviewed
Table 1. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (US$ Million) Growth Rate by Type (2020 & 2024 & 2031)
Table 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (US$ Million) Comparison by Application (2020 & 2024 & 2031)
Table 3. Global Market Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Region (2020-2025)
Table 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2020-2025)
Table 6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) Market Share by Region (2020-2025)
Table 7. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Region (2020-2025)
Table 8. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) Forecast by Region (2026-2031)
Table 9. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share Forecast by Region (2026-2031)
Table 10. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) Forecast by Region (2026-2031)
Table 11. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share Forecast by Region (2026-2031)
Table 12. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (K Units) & (2020-2025)
Table 13. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Type (2020-2025)
Table 14. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (US$ Million) & (2020-2025)
Table 15. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (US$/Unit) & (2020-2025)
Table 16. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (K Units) & (2026-2031)
Table 17. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (US$ Million) & (2026-2031)
Table 18. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (US$/Unit) & (2026-2031)
Table 19. Representative Players of Each Type
Table 20. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (K Units) & (2020-2025)
Table 21. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Application (2020-2025)
Table 22. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (US$ Million) & (2020-2025)
Table 23. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (US$/Unit) & (2020-2025)
Table 24. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (K Units) & (2026-2031)
Table 25. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (US$ Million) & (2026-2031)
Table 26. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (US$/Unit) & (2026-2031)
Table 27. New Sources of Growth in Chemotherapy Induced Peripheral Neuropathy Treatment Application
Table 28. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (K Units) & (2020-2025)
Table 29. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Company (2020-2025)
Table 30. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (US$ Million) & (2020-2025)
Table 31. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Company (2020-2025)
Table 32. Global Chemotherapy Induced Peripheral Neuropathy Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment as of 2024)
Table 33. Global Market Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Company (US$/Unit) & (2020-2025)
Table 34. Global Key Manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment, Manufacturing Sites & Headquarters
Table 35. Global Key Manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment, Product Type & Application
Table 36. Global Key Manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment, Date of Enter into This Industry
Table 37. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 38. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2020-2025) & (K Units)
Table 39. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company (2020-2025)
Table 40. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2020-2025) & (US$ Million)
Table 41. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Company (2020-2025)
Table 42. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2020-2025) & (K Units)
Table 43. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2020-2025)
Table 44. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2020-2025) & (K Units)
Table 45. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2020-2025)
Table 46. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2020-2025) & (K Units)
Table 47. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company (2020-2025)
Table 48. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2020-2025) & (US$ Million)
Table 49. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Company (2020-2025)
Table 50. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2020-2025) & (K Units)
Table 51. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2020-2025)
Table 52. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2020-2025) & (K Units)
Table 53. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2020-2025)
Table 54. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2020-2025) & (K Units)
Table 55. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company (2020-2025)
Table 56. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2020-2025) & (US$ Million)
Table 57. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Company (2020-2025)
Table 58. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2020-2025) & (K Units)
Table 59. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2020-2025)
Table 60. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2020-2025) & (K Units)
Table 61. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2020-2025)
Table 62. Aptinyx Inc Company Information
Table 63. Aptinyx Inc Description and Business Overview
Table 64. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 65. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 66. Aptinyx Inc Recent Development
Table 67. Asahi Kasei Pharma Corp Company Information
Table 68. Asahi Kasei Pharma Corp Description and Business Overview
Table 69. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 70. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 71. Asahi Kasei Pharma Corp Recent Development
Table 72. Regenacy Pharmaceuticals Company Information
Table 73. Regenacy Pharmaceuticals Description and Business Overview
Table 74. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 75. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 76. Regenacy Pharmaceuticals Recent Development
Table 77. MAKScientific LLC Company Information
Table 78. MAKScientific LLC Description and Business Overview
Table 79. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 80. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 81. MAKScientific LLC Recent Development
Table 82. Metys Pharmaceuticals AG Company Information
Table 83. Metys Pharmaceuticals AG Description and Business Overview
Table 84. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 85. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 86. Metys Pharmaceuticals AG Recent Development
Table 87. Nemus Bioscience Inc Company Information
Table 88. Nemus Bioscience Inc Description and Business Overview
Table 89. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 91. Nemus Bioscience Inc Recent Development
Table 92. PledPharma Company Information
Table 93. PledPharma Description and Business Overview
Table 94. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 95. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 96. PledPharma Recent Development
Table 97. Sova Pharmaceuticals Inc Company Information
Table 98. Sova Pharmaceuticals Inc Description and Business Overview
Table 99. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 100. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 101. Sova Pharmaceuticals Inc Recent Development
Table 102. DermaXon LLC Company Information
Table 103. DermaXon LLC Description and Business Overview
Table 104. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 105. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 106. DermaXon LLC Recent Development
Table 107. Kineta Inc Company Information
Table 108. Kineta Inc Description and Business Overview
Table 109. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 110. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 111. Kineta Inc Recent Development
Table 112. Krenitsky Pharmaceuticals Inc Company Information
Table 113. Krenitsky Pharmaceuticals Inc Description and Business Overview
Table 114. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 115. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 116. Krenitsky Pharmaceuticals Inc Recent Development
Table 117. PeriphaGen Company Information
Table 118. PeriphaGen Description and Business Overview
Table 119. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 120. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 121. PeriphaGen Recent Development
Table 122. Apexian Pharma Company Information
Table 123. Apexian Pharma Description and Business Overview
Table 124. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 125. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 126. Apexian Pharma Recent Development
Table 127. WinSanTor Company Information
Table 128. WinSanTor Description and Business Overview
Table 129. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 130. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 131. WinSanTor Recent Development
Table 132. Production Base and Market Concentration Rate of Raw Material
Table 133. Key Suppliers of Raw Materials
Table 134. Chemotherapy Induced Peripheral Neuropathy Treatment Distributors List
Table 135. Chemotherapy Induced Peripheral Neuropathy Treatment Customers List
Table 136. Chemotherapy Induced Peripheral Neuropathy Treatment Market Trends
Table 137. Chemotherapy Induced Peripheral Neuropathy Treatment Market Drivers
Table 138. Chemotherapy Induced Peripheral Neuropathy Treatment Market Challenges
Table 139. Chemotherapy Induced Peripheral Neuropathy Treatment Market Restraints
Table 140. Research Programs/Design for This Report
Table 141. Key Data Information from Secondary Sources
Table 142. Key Data Information from Primary Sources
List of Figures
Figure 1. Chemotherapy Induced Peripheral Neuropathy Treatment Product Picture
Figure 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (US$ Million) by Type (2020 & 2024 & 2031)
Figure 3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type in 2024 & 2031
Figure 4. Calcium Channel α2-delta Ligands Product Picture
Figure 5. Antidepressants Product Picture
Figure 6. Opioids Product Picture
Figure 7. Others Product Picture
Figure 8. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (US$ Million) by Application (2020 & 2024 & 2031)
Figure 9. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application in 2024 & 2031
Figure 10. Platinum Agents Examples
Figure 11. Taxanes Examples
Figure 12. Vinca Alkaloids Examples
Figure 13. Others Examples
Figure 14. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2020-2031) & (US$ Million)
Figure 16. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) Growth Rate (2020-2031)
Figure 17. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price Trends Growth Rate (2020-2031) & (US$/Unit)
Figure 18. Chemotherapy Induced Peripheral Neuropathy Treatment Report Years Considered
Figure 19. Global Market Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Figure 20. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region: 2020 VS 2024
Figure 21. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) Growth Rate (2020-2031)
Figure 22. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) Growth Rate (2020-2031)
Figure 23. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) Growth Rate (2020-2031)
Figure 24. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) Growth Rate (2020-2031)
Figure 25. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) Growth Rate (2020-2031)
Figure 26. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) Growth Rate (2020-2031)
Figure 27. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Type (2020-2025)
Figure 28. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Type (2026-2031)
Figure 29. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Type (2026-2031)
Figure 30. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Application (2020-2025)
Figure 31. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate by Application in 2020 & 2024
Figure 32. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Application (2026-2031)
Figure 33. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Application (2026-2031)
Figure 34. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Company (2024)
Figure 35. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Company (2024)
Figure 36. Global 5 Largest Chemotherapy Induced Peripheral Neuropathy Treatment Players Market Share by Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment: 2020 & 2024
Figure 37. Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 38. Manufacturing Cost Structure of Chemotherapy Induced Peripheral Neuropathy Treatment
Figure 39. Manufacturing Process Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment
Figure 40. Chemotherapy Induced Peripheral Neuropathy Treatment Industrial Chain
Figure 41. Channels of Distribution (Direct Vs Distribution)
Figure 42. Distributors Profiles
Figure 43. Bottom-up and Top-down Approaches for This Report
Figure 44. Data Triangulation
Figure 45. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Smart Grid Digital Substation Market Research Report 2026
Mar 17, 26
Global Photovoltaic Molded Case Circuit Breaker Market Research Report 2026
Mar 17, 26
Global Roll-Roll Automobile Business Market Research Report 2026
Mar 17, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232